Victory Capital Management
FHTX icon

Victory Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Victory Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,500
Closed -$322K – 2631
2022
Q3 		$322K Buy
+37,500
New +$483K ﹤0.01% 2225
2021
Q2 		– Sell
-16,190
Closed -$213K – 2773
2021
Q1 		$213K Sell
16,190
-76,880
-83% -$1.26M ﹤0.01% 2515
2020
Q4 		$1.89M Buy
+93,070
New +$1.78M ﹤0.01% 1540

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management's FHTX Position: Q4 2022 in Review

Victory Capital Management sold out of Foghorn Therapeutics (FHTX) in Q4 2022, closing a stake of 37,500 shares — an estimated $322K sold.

Victory Capital Management first reported a position in FHTX in Q4 2020 and held it in 3 quarters. The position peaked at $1.89M in Q4 2020. 65 funds tracked by Wall St. Rank hold FHTX as of Q4 2022.

  • Victory Capital Management reported no remaining Foghorn Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Victory Capital Management sold 37,500 Foghorn Therapeutics shares in Q4 2022, an estimated $322K.
  • Victory Capital Management first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 3 quarters.
  • Victory Capital Management's Foghorn Therapeutics position peaked at $1.89M in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.